{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:13:33Z","timestamp":1786115613159,"version":"build-2736575974"},"reference-count":23,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Dermatology"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, is approved in multiple countries for the treatment of moderate to severe plaque psoriasis, as well as generalized pustular and erythrodermic psoriasis in Japan. Deucravacitinib 6\u2009mg once daily was efficacious and well tolerated through 3\u2009years in the pooled population of Japanese patients in the POETYK PSO\u20101 and PSO\u20104 trials who entered the ongoing open\u2010label POETYK long\u2010term extension trial. Safety and efficacy of deucravacitinib were evaluated through 5\u2009years (256\u2009weeks; data cutoff September 2, 2024) in Japanese patients who received continuous deucravacitinib in PSO\u20101 or PSO\u20104 or who crossed over from placebo to deucravacitinib at Week 16 in PSO\u20101. Safety was evaluated via adverse event (AE) exposure\u2010adjusted incidence rates (EAIRs); efficacy was evaluated via endpoints including \u2265\u200975% reduction from baseline in the Psoriasis Area and Severity Index (PASI 75) and static Physician Global Assessment (sPGA) score of 0\/1 (clear\/almost clear). At data cutoff, 136 patients had received at least one deucravacitinib dose; 77.2% had &gt;\u200948\u2009months and 39.7% had &gt;\u200960\u2009months of total deucravacitinib exposure. EAIRs per 100 person\u2010years were 182.1 (any AEs), 6.9 (serious AEs), 3.0 (discontinuations due to AEs), 1.6 (serious infections), 1.6 (herpes zoster events), 0.5 (major adverse cardiovascular events), and 1.4 (malignancies). Clinical responses (as observed) were maintained over 5\u2009years in PSO\u20101 patients receiving continuous deucravacitinib treatment from baseline (PASI 75: Year 1, 88.9%; Year 5, 85.7%; sPGA 0\/1: Year 1, 74.1%; Year 5, 71.4%); results were consistent regardless of imputation method (modified nonresponder imputation, treatment failure rule). Year 1 response rates were also maintained through Year 5 in PSO\u20104 patients and in PSO\u20101 patients who crossed over from placebo. These findings support the long\u2010term safety and durable efficacy profile of deucravacitinib through 5\u2009years in Japanese patients with psoriasis.<\/jats:p>","DOI":"10.1111\/1346-8138.70392","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T03:45:08Z","timestamp":1785987908000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and Efficacy of Deucravacitinib in Japanese Patients With Moderate to Severe Plaque Psoriasis: 5\u2010Year Analysis of the Phase 3\n                    <scp>POETYK PSO<\/scp>\n                    \u20101,\n                    <scp>PSO<\/scp>\n                    \u20104, and Long\u2010Term Extension Trials"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9526-1259","authenticated-orcid":false,"given":"Yukari","family":"Okubo","sequence":"first","affiliation":[{"name":"Department of Dermatology Tokyo Medical University  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8372-3754","authenticated-orcid":false,"given":"Akimichi","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Geriatric and Environmental Dermatology Nagoya City University Graduate School of Medical Sciences  Nagoya City Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3743-135X","authenticated-orcid":false,"given":"Yayoi","family":"Tada","sequence":"additional","affiliation":[{"name":"Department of Dermatology Teikyo University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8568-4349","authenticated-orcid":false,"given":"Shinichi","family":"Imafuku","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Faculty of Medicine Fukuoka University  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0064-8707","authenticated-orcid":false,"given":"April W.","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of California Los Angeles  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2633-985X","authenticated-orcid":false,"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of Maryland School of Medicine  Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Vaile","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoran","family":"Popmihajlov","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Li","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Sawant","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyoshi","family":"Habiro","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuki","family":"Tsuritani","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7845-6698","authenticated-orcid":false,"given":"Mamitaro","family":"Ohtsuki","sequence":"additional","affiliation":[{"name":"Department of Dermatology Jichi Medical University  Tochigi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.82"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-006450"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-017-0205-2"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw1736"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.07.004"},{"key":"e_1_2_11_7_1","volume-title":"Sotyktu","year":"2026"},{"key":"e_1_2_11_8_1","volume-title":"Sotyktu","year":"2022"},{"key":"e_1_2_11_9_1","volume-title":"Sotyktu","year":"2022"},{"key":"e_1_2_11_10_1","volume-title":"Sotyktu","year":"2023"},{"key":"e_1_2_11_11_1","volume-title":"Sotyktu","year":"2023"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.07.002"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.08.061"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16740"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17074"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17685"},{"key":"e_1_2_11_17_1","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jamadermatol.2024.4688","article-title":"Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for up to 3\u2009Years: An Open\u2010Label Extension of Randomized Clinical Trials","volume":"161","author":"Armstrong A. W.","year":"2025","journal-title":"JAMA Dermatology"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae014"},{"key":"e_1_2_11_19_1","unstructured":"A. W.Armstrong M.Lebwohl R. B.Warren et\u00a0al. \u201cDeucravacitinib 5\u2010Year Safety and Efficacy in Plaque Psoriasis: A Phase 3 Open\u2010Label Extension of Randomized Clinical Trials.American Journal of Clinical Dermatology.In press (2026)."},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2021.10.007"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104488"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.5114\/ada.2020.94835"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-021-01080-z"},{"key":"e_1_2_11_24_1","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aau8714","article-title":"Tuberculosis and Impaired IL\u201023\u2010Dependent IFN\u2010Gamma Immunity in Humans Homozygous for a Common TYK2 Missense Variant","volume":"3","author":"Boisson\u2010Dupuis S.","year":"2018","journal-title":"Science Immunology"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.70392","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1346-8138.70392","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.70392","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T03:45:10Z","timestamp":1785987910000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.70392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":23,"alternative-id":["10.1111\/1346-8138.70392"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.70392","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"assertion":[{"value":"2026-04-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"1346-8138.70392"}}